AR-Negative Prostate Cancer Is Vulnerable to Loss of JMJD1C Demethylase

Scientists performed comparative transcriptomics of 1) isogenic androgen receptor (AR)-positive versus AR-negative prostate cancer cells, 2) AR-positive versus AR-negative prostate cancer tumors, and 3) isogenic JMJD1C-expressing versus JMJD1C-depleted AR-negative prostate cancer cells.